This construct allows us to selectively eliminate SORE6+-CSCs in the bulk of tumors and provides compelling evidence that SOX2/OCT4 overexpression in prostate CSCs contributes to tumor initiation, progression, and tumor relapse from chemotherapy. The gene discussed is POU5F1; the disease is neoplasm.